- Martyn Coombs - Chief Executive Officer
- Jeff Quan - Chief Financial Officer
- Jean Gudas, PhD - Vice President, Research and Development
- William Le - Senior Director, Clinical Development
- Andrew Dorr, MD - Interim Chief Medical Officer
- Robert E. Reiter, MD - Chief Medical Advisor, Co-Founder
Chief Executive Officer
Mr. Coombs is a recognized Industry Leader in Nuclear Medicine and Imaging. Most recently, as President of Jubilant DraxImage, he led the company through a period of rapid organic growth, tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill®, a key PET Cardiology product. Mr. Coombs has held senior leadership roles at Amersham (now GE Healthcare), and Nihon Medi-Physics, where he was the number two Executive. Previously, he has served as CEO of Asterand PLC, a public life sciences company, where in 2008 he received an award from The Financial Times for the top performing stock on the London Stock Exchange, out of more than 2,000 companies. He has lived and worked in North America, Japan, and Europe. Mr. Coombs holds a degree in Mathematics, and an MBA with distinction from Warwick Business School.
Chief Financial Officer
Mr. Quan has over 25 years of operational, financial and transactional experience in industries that include life sciences, technology, communications, manufacturing and distribution. He has led a wide variety of organizations, including VC-funded-to-mature entities, through rapid growth, complex capital raise initiatives, various business combinations and post-transactional integrations. Immediately prior to joining ImaginAb, he served as CFO at Cooking.com and was responsible for the company’s bridge financing which preceded the sale to Target Stores. He also served as CFO of a $100 million Motorola subsidiary which was led back to profitability. Mr. Quan previously served as Managing Director at Platinum Equity’s Tokyo office. He has also served as EVP and COO at Takenaka Partners, an investment bank focused on cross-border deals involving Global Fortune 500 entities in Japan and other parts of Asia. He brings a strong financial operations and transactional track record to the team. Mr. Quan holds undergraduate degrees in Economics and Political Science from the University of California, Los Angeles.
Vice President, Research and Development
Dr. Gudas joined ImaginAb in August 2012 and brings broad experience in the research and development of monoclonal antibody and antibody drug conjugates to the position. She has an excellent working knowledge of the multiple facets of drug development from target discovery and validation, through lead candidate selection and optimization, preclinical efficacy, safety evaluation, IND submissions and translational biology. Prior to joining ImaginAb, she held the position of Senior Director of Preclinical Development at both Kite Pharma and Agensys/Astellas where she advanced a portfolio of novel, proprietary cancer targets and established a clinical pipeline of therapeutic human antibodies in multiple cancer indications. Her contributions have resulted in the progression of multiple antibody candidate therapeutics into clinical trials. Dr. Gudas received a dual degree in Microbiology and Chemistry from the University of Rhode Island, a Master’s degree in Microbiology and Immunology from the University of Oklahoma and a PhD degree from UCLA.
Senior Director, Clinical Development
Mr. Le joined ImaginAb to lead the clinical development effort that includes Clinical Operations, Program and Project Management, and Strategic Alliance Management. Mr. Le has 14 years of industry experience in clinical research and cross-functional leadership in biotechnology and pharmaceutical drug development from Phase I–IV. Prior to joining ImaginAb, Mr. Le was the Senior Director of Clinical Operations at Gradalis Inc., a start-up biotechnology company developing personalized molecular-based immuno-oncology therapies, functioning in a similar leadership role and capacity. Prior to Gradalis, Mr. Le held various Clinical Operations leadership roles at Spectrum Pharmaceuticals where he managed and successfully completed two registration studies that were submitted for New Drug Application (NDA) review, resulting in one (Beleodaq®) being approved for the treatment of a rare cancer. Mr. Le obtained his Bachelor’s degree in Management from Oklahoma State University and his Master’s degree in Biotechnology Management from the University of Maryland University College.
Interim Chief Medical Officer
Dr. Dorr is a medical oncologist with a long history of successful cancer drug development experience, with leadership participation in the development of Gemzar (gemcitabine) in pancreatic and non-small cell lung cancers, Treanda (bendamustine) in chronic lymphocytic leukemia and non-Hodgkin lymphoma as well as Avastin (bevacizumab) in glioblastoma. Dr. Dorr has had a successful consulting business in cancer drug development since 2005. Previously, he served as Chief Operating Officer at Salmedix Inc. from April 2003 until August 2004. From June 1996 to March 2003, he served as Vice President of oncology drug development at Isis (now Ionis) Pharmaceuticals, Inc. and served as its Chief Medical Officer. He also served as clinical research physician and then medical advisor at Eli Lilly & Company where he was responsible for the strategy for Lilly’s cancer pipeline from pre-clinical through Phase III development. While at the National Cancer Institute, he was responsible for national clinical trial programs in breast cancer, prostate, kidney, bladder and testicular cancers, as well as melanoma. Dr. Dorr has over 60 publications on drug development in books and journals.Dr. Dorr received his B.S. degree from Davidson College and holds his M.D. from the University of North Carolina at Chapel Hill.
Chief Medical Advisor, Co-Founder
Dr. Reiter is a Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. As co-developer of ImaginAb’s technology and Chief Medical Advisor, Dr. Reiter helps ensure high clinical impact and relevance by guiding the validation studies for ImaginAb’s clinical imaging pipeline. Dr. Reiter is a prominent figure in prostate cancer research and treatment, and is currently the Director of the Genitourinary Cancer Program in the Jonsson Comprehensive Cancer Center and the Director of Research in the Department of Urology at UCLA. Dr. Reiter completed his undergraduate studies at Yale University and medicine at Stanford University Medical School.